Pharmaceutical LSD reports one of the largest antidepressant effect sizes on record
A Phase 3 trial of a pharmaceutical LSD formulation for major depression reported a large, rapid, and durable reduction in symptoms, meeting its primary and secondary endpoints, among the strongest effect sizes reported for any antidepressant in a controlled trial. Independent, non-industry replication and peer-reviewed publication are the next tests.
Reported June 2026 · late-stage clinical trial data · reliability: strong signal, awaiting full peer review.
A 2026 meta-analysis finds a standard psilocybin dose clearly beats control for depression
Pooling six randomized controlled trials, a meta-analysis found a standard (25 mg) psilocybin dose superior to control for major depression, with higher response and remission rates sustained for weeks, and lower dropout than control. A low dose showed no such advantage. It's some of the firmest evidence yet that dose and context matter.
Kishi et al., Journal of Affective Disorders, 2026 · meta-analysis of 6 RCTs · reliability: strong (peer-reviewed).
U.S. regulators grant their first priority reviews for psychedelic therapies
In 2026 the FDA issued national priority vouchers to several psychedelic programs, including psilocybin for depression and an MDMA-analog for PTSD, a mechanism that can compress review timelines substantially. It's a signal of how quickly the regulatory landscape is shifting, even as these substances remain federally controlled.
Reported 2026 · regulatory action · reliability: strong (official).
Antidepressant effect of a single psilocybin course appears to last up to a year
A 12-month follow-up from a European trial reported that the antidepressant effect of psilocybin, given alongside psychological support, was still measurable a year later. Long-term, real-world durability across larger and more diverse groups remains an open question.
EPIsoDE follow-up, Psychotherapy and Psychosomatics, 2026 · reliability: moderate–strong (peer-reviewed, single trial).
The honest caveat we attach to all of it
Most of this research asks whether psychedelics can treat illness. Metanoia's question is different, whether, used carefully, they can help healthy people thrive, and there the evidence is genuinely promising but far less settled. We report the field as it is: the strong results and the thin ones, side by side. None of this is medical or legal advice, and these substances remain controlled in most places.